2BO

F:2BO Germany Biotechnology
Market Cap
$12.81 Million
€12.48 Million EUR
Market Cap Rank
#30482 Global
#3377 in Germany
Share Price
€1.17
Change (1 day)
-4.10%
52-Week Range
€1.17 - €3.12
All Time High
€3.12
Categories
Companies in Germany Biotechnology
About

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in preclinical stage development; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214 … Read more

2BO (2BO) - Cash Flow Conversion Efficiency

Latest cash flow conversion efficiency as of September 2025: -2.415x

Based on the latest financial reports, 2BO (2BO) has a cash flow conversion efficiency ratio of -2.415x as of September 2025.

Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.85 Million) by net assets (€1.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

2BO - Cash Flow Conversion Efficiency Trend (2021–2024)

This chart illustrates how 2BO's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.

2BO Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of 2BO ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Kanoria Chemicals & Industries Limited
NSE:KANORICHEM
 		0.015x
Electric Royalties Ltd
OTCQB:ELECF
 		-0.011x
Mountain Alliance AG
XETRA:ECF
 		-0.021x
Strong Petrochemical Holdings Limited
F:K20A
 		0.006x
Jeju Beer Co. Ltd.
KQ:276730
 		-0.248x
Natural Capsules Limited
NSE:NATCAPSUQ
 		0.022x
AIM ImmunoTech Inc
NYSE MKT:AIM
 		0.612x
Zhong Yang Financial Group Limited Ordinary Shares
NASDAQ:TOP
 		0.209x

Annual Cash Flow Conversion Efficiency for 2BO (2021–2024)

The table below shows the annual cash flow conversion efficiency of 2BO from 2021 to 2024.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €508.00K €-17.14 Million -33.734x -44098.95%
2023-12-31 €-32.29 Million €-2.48 Million 0.077x +39.55%
2022-12-31 €-37.78 Million €-2.08 Million 0.055x -14.30%
2021-12-31 €-35.11 Million €-2.25 Million 0.064x --